<DOC>
	<DOCNO>NCT00246259</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , safety tolerability risperidone long-acting injection ( LAI ) versus oral antipsychotic participant recent onset psychosis ( abnormal thinking and/or hallucination ) .</brief_summary>
	<brief_title>A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic Treatment Early Psychosis</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study drug assign chance ) , multicenter ( conduct 1 center ) , exploratory study participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality ) schizoaffective disorder ( mixed psychiatric disorder relate complex psychotic state feature schizophrenia mood disorder ) . Duration study 24 month . Study assessment visit conduct Screening , Baseline , Week 2 , every 4 week till Week 22 , Week 28 , every 12 week till Week 88 Week 104 . All eligible participant receive either risperidone long act injection 25 milligram ( mg ) intramuscularly ( muscle ) along current oral medication ( atypical antipsychotic - risperidone , quetiapine , olanzapine ) current oral medication . Efficacy evaluate primarily Positive Negative Syndromes Scale ( PANSS ) , time relapse Social Occupational Functioning Assessment Scale ( SOFAS ) . Participants 's safety evaluate throughout study mainly Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Rating Scale ( BARS ) , Simpson Angus Scale ( SAS ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Inpatients outpatient Primary Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) diagnosis schizophrenia , schizophreniform disorder schizoaffective disorder longer 3 year diagnosis treatment psychotic illness Positive Negative Syndrome Scale ( PANSS ) score 60120 Visit 1 2 Currently monotherapy atypical antipsychotic treatment local label guideline treatment naive Able complete selfassessments either English French Current primary Axis1 diagnosis schizophrenia , schizophreniform disorder schizoaffective disorder , accord DSMIV Current drug alcohol dependence Treatment depot antipsychotic within 3 month study start Confirmed suspect history lack tolerability , hypersensitivity allergy risperidone Risperidone nonresponders ( base evidence adequate trial treatment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Schizophreniform disorder</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal Consta</keyword>
</DOC>